Literature DB >> 7506158

Nimesulide and diclofenac in the control of cancer-related pain. Comparison between oral and rectal administration.

O Corli1, A Cozzolino, I Scaricabarozzi.   

Abstract

64 patients with pain associated with advanced cancer were treated with either nimesulide or diclofenac as initial analgesia. Patients were randomly allocated to 1 of 4 treatment groups: oral nimesulide 300 mg/day; oral diclofenac 150 mg/day; rectal nimesulide 400 mg/day; and rectal diclofenac 200 mg/day. After 1 week of treatment, both drugs provided an adequate degree of pain relief and allowed an increase in sleep duration. There were no significant differences in efficacy between the drugs or routes of administration. Fewer side effects were observed with nimesulide, giving this agent a better therapeutic index than the reference compound.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506158     DOI: 10.2165/00003495-199300461-00036

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  6 in total

1.  Inhibition of neutrophil oxidative metabolism by nimesulide.

Authors:  F Capsoni; E Venegoni; F Minonzio; A M Ongari; V Maresca; C Zanussi
Journal:  Agents Actions       Date:  1987-06

2.  Diclofenac does not modify morphine bioavailability in cancer patients.

Authors:  Franco De Conno; Carla Ripamonti; Mauro Bianchi; Vittorio Ventafridda; Alberto E Panerai
Journal:  Pain       Date:  1992-03       Impact factor: 6.961

Review 3.  Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states.

Authors:  A Ward; R N Brogden
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

4.  4-nitro-2-phenoxymethanesulfonanilide (R-805): a chemically novel anti-inflammatory agent.

Authors:  K F Swingle; G G Moore; T J Grant
Journal:  Arch Int Pharmacodyn Ther       Date:  1976-05

5.  Sodium naproxen versus sodium diclofenac in cancer pain control.

Authors:  V Ventafridda; F Toscani; M Tamburini; O Corli; M Gallucci; A Gottlieb; R Speranza; F De Conno
Journal:  Arzneimittelforschung       Date:  1990-10

Review 6.  Use of non-steroidal anti-inflammatory drugs in the treatment of pain in cancer.

Authors:  V Ventafridda; C Fochi; D De Conno; E Sganzerla
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

  6 in total
  3 in total

Review 1.  Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults.

Authors:  Sheena Derry; Philip J Wiffen; R Andrew Moore; Ewan D McNicol; Rae F Bell; Daniel B Carr; Mairead McIntyre; Bee Wee
Journal:  Cochrane Database Syst Rev       Date:  2017-07-12

Review 2.  Adverse drug events related to dosage forms and delivery systems.

Authors:  I F Uchegbu; A T Florence
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

Review 3.  Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  R Davis; R N Brogden
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.